Ipamorelin dosage, strictly as the studies administered it

Read this first

This page lists the ipamorelin doses used in actual studies, in animals and in the two human datasets. It is not instructions. Nobody here is telling you a number to use — there is no established human dose for ipamorelin, because the drug was never approved and the one human efficacy trial didn't work.

The useful, real facts are about timing. In people, ipamorelin clears fast — a roughly 2-hour half-life — and produces one short burst of growth hormone that peaks about 40 minutes after dosing ^[2]. That "quick in, quick out" behavior is the single most important thing the human data tell us. Everything below is reported in the third person, exactly as administered in the literature, with community "stack" numbers flagged as having no controlled human basis at all.

Doses used in the studies

Here is the documented record, by study and species — research context only, never a recommendation:

• Human PK/PD study: 4.21–140.45 nmol/kg IV over 15 minutes, single doses ^[2].
• Human Phase 2 ileus trial: 0.03 mg/kg IV twice daily for up to 7 days ^[3].
• Rat bone-growth study: 18, 90, 450 µg/day subcutaneously, divided three times daily, 15 days ^[4].
• Rat postoperative-ileus study: 0.1–1 mg/kg IV, repeated four times daily ^[11].
• Ferret cachexia study (2024): 1–3 mg/kg intraperitoneal ^[5].

Notice these are mostly intravenous and mostly in animals. The route most people actually use in the community — subcutaneous self-injection — appears in the rodent literature, but has never been characterized for dose or safety in humans ^[2].

Half-life and timing

The human pharmacokinetics come from one careful study. In healthy male volunteers, ipamorelin showed dose-proportional kinetics with a terminal half-life of about 2 hours, clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg ^[2]. The growth hormone response was a single discrete pulse peaking at roughly 0.67 h — about 40 minutes — after dosing ^[2]. In rats, plasma clearance runs roughly 5-fold lower than the older peptide GHRP-6 ^[2].

The practical read: ipamorelin is a pulse generator, not a steady-state hormone. It spikes GH once and then exits within a few hours. That kinetic shape — not any anti-aging promise — is what genuinely distinguishes it on paper.

Routes studied

Ipamorelin has been administered by several routes across the literature, each in a specific research context: intravenous (the human PK and clinical trials, plus rodent efficacy work); subcutaneous (rodent bone and body-composition studies, and the dominant route in community use); intranasal (rodent PK, around 20% bioavailability); and intraperitoneal (rodent and ferret efficacy studies) ^[2][4][5]. Ipamorelin itself is not orally bioavailable — only engineered ipamorelin-derived analogs achieve meaningful oral absorption (around 10% in dogs). None of these route notes constitutes a usage instruction.

How much cjc-1295 ipamorelin should i take

There is no answer to how much cjc-1295 ipamorelin should i take that the published literature can support — and this site will not invent one. No controlled human trial has ever tested the cjc-1295 ipamorelin combination at any dose, for any outcome ^[3]. The subcutaneous "stack" regimens circulated in peptide forums have no peer-reviewed human dosing basis; they are anecdotal community practice, not a validated protocol, and they are not a recommendation here. The only human ipamorelin dosing on record is the IV research described above ^[2][3].

How to reconstitute cjc-1295 ipamorelin 5mg

On how to reconstitute cjc-1295 ipamorelin 5mg: ipamorelin is supplied as a lyophilized (freeze-dried) powder — free base or acetate salt — and is reconstituted with bacteriostatic water for research handling. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated ^[2]. These are general peptide-handling observations from the research-supply literature, not a clinical preparation instruction and not a directive to prepare or inject anything. There is no approved cjc-1295 ipamorelin product and no labeled preparation procedure to follow.